Gyre Therapeutics Inc. (GYRE NASDAQ) stock market data APIs
$8.37
-0.27(-3.2%)
as of October 13, 2025
Try our APIs with
free plan!
Gyre Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Prev. Close
8.37
Open
8.1004
High
8.4512
Low
8.1004
52 wk Range
6.11-19
Market Cap
723 M
P/E Ratio
398
Shares Outstanding
90 827 K
Revenue
102 M
EPS
0.0022
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Gyre Therapeutics Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Gyre Therapeutics Inc. data using free add-ons & libraries
Get Gyre Therapeutics Inc. Fundamental Data
Gyre Therapeutics Inc. Fundamental data includes:
- Net Revenue: 102 M
- EBITDA: 11 462 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-11
- EPS/Forecast: 0.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Gyre Therapeutics Inc. News
New
Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength?
Septerna, Inc. (SEPN) shares soared 7% in the last trading session to close at $22.49. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares t...
Discovering 3 Undiscovered Gems In The US Market
As the U.S. market faces potential volatility with major stock indexes experiencing slight fluctuations ahead of a government shutdown deadline, investors are keenly observing economic indicators that...
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies...
Jefferies initiates coverage on Crescent Biopharma stock with Buy rating
Investing.com - Jefferies initiated coverage on Crescent Biopharma Inc (NASDAQ:CBIO) with a Buy rating and set a price target of $26.00. The stock, currently trading at $15.06, has shown strong moment...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
